RAGE406R
RAGE406R is an orally active RAGE-DIAPH1 interaction antagonist. RAGE406R can bind to ctRAGE and prevent the formation of the RAGE-DIAPH1 complex and inhibit its interaction. RAGE406R can reduce the expression of CCL2, TNF, and IL-6 in THP1 cells. RAGE406R suppresses delayed-type hypersensitivity in T2D mice. RAGE406R can be used for the study of diabetes.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3034560-21-6
- Fòrmula: C25H24N4O2
- Peso molecular:412.48
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
Descripciòn
IC50 & Target
[1]|
IL-6 |
In Vitro
RAGE406R (8.1 nM) inhibits the activation of DIAPH1 actin polymerization activity by ctRAGE by antagonizing the interaction between ctRAGE and DIAPH1[1].
RAGE406R (0.1-5.0 μM, 1 h) dose-dependently reduces the intracellular proximity of RAGE and DIAPH1. After adding 0.1 μM RAGE406R, the FRET efficiency decreases to 4.7 %; at 5.0 μM, it decreased to 1.6 %[1].
RAGE406R (0.00006-10 μM, 1.5 h) increases the inhibition of RAGE ligand-stimulated SMC migration, with an IC50 of 2 nM in murine aortic SMCs[1].
RAGE406R (10 μM, 1.5 h) significantly reduces the expression of CCL2, TNF, and IL-6 in THP1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Primary murine aortic SMCs
-
Concentration:0.00006 μM, 0.0002 μM, 0.001 μM, 0.002 μM, 0.005 μM, 0.014 μM, 0.041 μM, 0.123 μM, 0.370 μM, 1.111 μM, 3.333 μM, 10 μM
-
Incubation Time:1.5 h
-
Result:Increased the inhibition of RAGE ligand-stimulated SMC migration, with an IC50 of 2 nM in murine aortic SMCs.
-
Cell Line:THP1 cells
-
Concentration:10 μM
-
Incubation Time:1.5 h
-
Result:Significantly reduced the expression of CCL2, TNF, and IL6 in THP1 cells.
In Vivo
RAGE406R (5 mg/kg, topical application, twice daily for 8 days) accelerates the healing of diabetic wounds in mice and has a more comprehensive anti-inflammatory effect in males[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CF-1 mice were immunosensitized by injection of methylated bovine serum albumin (mBSA) (immunogen being mBSA + Freund's incomplete adjuvant emulsion) into the left inguinal lymph node. Three weeks later, an inflammatory response was elicited by injection of mBSA (20 μg) into the left hind paw pad[1].
-
Dosage:5 mg/kg
-
Administration:P.o., twice daily (12-hour intervals) for a total of 4 doses
-
Result:Inflammation score significantly reduced.
-
Animal Model:Full-thickness 1 cm × 1 cm excisional wounds were created on the backs of male and female mouse models of T2D, ob/ob mice; wounds were covered with Tegaderm clear dressing[1].
-
Dosage:5 mg/kg
-
Administration:Topical application, twice daily for 8 days
-
Result:Significantly promoted wound closure.
Inflammation was reduced, collagen deposition increased, and epithelial migration accelerated.
In male mice, the expression of Ccl2, TNF, and IL-6 was significantly reduced; in female mice, only Ccl2 expression was significantly decreased, while TNF and IL-6 showed no significant changes.
Chemical Information
-
No. CAS 3034560-21-6
-
Peso molecular 412.48
-
Fòrmula C25H24N4O2
-
SMILES
N#CC1=CC=C2C(CN3CCOCC3)=CC(C4=CC=C(C=C4)[C@H]5CCC(N5)=O)=NC2=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Contact Hypersensitivity Dermatitis
Contact hypersensitivity (CHS) dermatitis is a T cell-mediated delayed-type (Type IV) immune reaction in which low-molecular-weight haptens applied to the skin bind host proteins to form complete antigens, triggering sensitization followed by a secondary inflammatory response upon re-exposure (elicitation phase), which is commonly quantified by ear swelling as a readout of skin inflammation in murine models. This model is widely used to study allergic contact dermatitis because it is antigen-specific, reproducible, and reflects key immunological events including dendritic cell activation, T cell priming in draining lymph nodes, and effector T cell-driven tissue inflammation. DNFB- and oxazolone-induced CHS models are standard systems for evaluating both acute and chronic T cell-dependent skin inflammation and for testing immunomodulatory interventions.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)